HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report) traded up 5.7% on Wednesday . The company traded as high as $2.59 and last traded at $2.59. 100 shares changed hands during trading, a decline of 88% from the average session volume of 837 shares. The stock had previously closed at $2.45.
Analyst Ratings Changes
Separately, Raymond James lowered their price target on HLS Therapeutics from $6.50 to $5.00 and set a “market perform” rating on the stock in a research report on Monday, March 18th.
View Our Latest Stock Report on HLTRF
HLS Therapeutics Price Performance
HLS Therapeutics Company Profile
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.
Recommended Stories
- Five stocks we like better than HLS Therapeutics
- Options Trading – Understanding Strike Price
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- Investing in Travel Stocks Benefits
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
